Arcadia Biosciences Release: U.S. FDA Publishes Final Rule Amending Food Regulations For Use Of SONOVA GLA Safflower Oil In Dog Food

Published: Aug 15, 2017

-- Arcadia Biosciences Launches Sales of SONOVA GLA Safflower Oil as a Healthy Ingredient and Rich Source of Omega-6 Fatty Acids --

DAVIS, Calif.--(BUSINESS WIRE)--Arcadia Biosciences, Inc. (Nasdaq: RKDA), an agricultural technology company, announced today that the U.S. Federal Register has published the Food and Drug Administration’s (FDA) approval of Arcadia’s food additive petition that its SONOVA® GLA safflower oil is safe and nutritious for use in dog diets. This approval allows Arcadia to launch sales of its SONOVA GLA safflower oil to pet nutrition companies as a rich source of omega-6 fatty acids in their dog food formulations.

Arcadia’s SONOVA gamma linolenic acid (GLA) safflower oil is a highly-concentrated source of omega-6 fatty acids GLA and linoleic acid (LA) and has been used in human nutritional supplements since its approval by the FDA in 2009. Clinical studies have shown that GLA offers similar benefits for pets, including weight management, control of pruritus and other dermatological conditions, mobility-related arthritic conditions and immune system disorders. Arcadia’s SONOVA GLA safflower oil contains a minimum of 40 percent GLA, which is approximately two to four times greater than most other commercial sources, making it the most concentrated and cost-effective plant oil source of GLA available.

“The Federal Register publication completes FDA’s approval of SONOVA GLA safflower oil and, beginning today, opens up an entirely new market for the sale of GLA in the fast-growing specialty market of pet nutrition,” said Raj Ketkar, president and CEO of Arcadia Biosciences. “GLA safflower oil is now the only approved source of gamma linolenic acid for use in dog food in the U.S.”

Publication in the Federal Register completes the issuance of a new food regulation: “Title 21, Code of Federal Regulations (21 CFR), part 573 – Food Additives Permitted in Feed and Drinking Water of Animals – be amended to provide for the safe use of gamma-linolenic acid (GLA) safflower oil as a source of omega-6 fatty acids in dry food for adult dogs.” FDA concluded that it had completed its review and found that “the data adequately support the safety and functionality of GLA safflower oil as a source of omega-6 fatty acids in dry food for adult dogs.”

For more information on Arcadia’s SONOVA GLA for use in pet food, visit: www.sonovaglapet.com.

About Arcadia Biosciences, Inc.

Based in Davis, Calif., Arcadia Biosciences (Nasdaq: RKDA) develops agricultural products that create added value for farmers while benefitting the environment and enhancing human health. Arcadia’s agronomic performance traits, including Nitrogen Use Efficiency, Water Use Efficiency, Salinity Tolerance, Heat Tolerance and Herbicide Tolerance, are all aimed at making agricultural production more economically efficient and environmentally sound. Arcadia’s nutrition traits and products are aimed at creating healthier ingredients and whole foods with lower production costs. For more information, visit www.arcadiabio.com.

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s GLA safflower oil products and the regulatory process for such products. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company’s and its partners’ and affiliates’ ability to identify and isolate desired traits; the company’s and its partners’ ability to develop commercial products incorporating GLA safflower oil, and complete the regulatory review process for such products; the company’s compliance with laws and regulations that impact the company’s business, and changes to such laws and regulations; the company’s future capital requirements and ability to satisfy its capital needs; and the other risks set forth in the company’s filings with the Securities and Exchange Commission from time to time, including the risks set forth in the company’s Annual Report on Form 10-K for the year ended December 31, 2016. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements.

Arcadia Biosciences, Inc.
Jeff Bergau
jeff.bergau@arcadiabio.com
+1-312-217-0419

Back to news